Home › Funds › Capricorn Fund Managers Ltd › CYTK
Capricorn Fund Managers Ltd position in CYTK
CYTOKINETICS INC · Health Care
Capricorn Fund Managers Ltd reported holding 240,200 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$15.8M, representing 1.52% of its reported portfolio and ranking #19 among its reported holdings. Capricorn Fund Managers Ltd has disclosed CYTK holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Capricorn Fund Managers Ltd's CYTK position evolved
Capricorn Fund Managers Ltd first disclosed a stake in CYTK in Q2 2026 at 81,879 shares (US$7.0M). The position peaked in Q3 2026 at 240,200 shares, worth US$15.8M. Across 2 filings, Capricorn Fund Managers Ltd increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 240,200 shares valued at US$15.8M — an increase of 158,321 shares quarter over quarter.. Notable position changes include a 193% increase in Q3 2026 (shares fell 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 81.88K | $6.98M | New |
| Q3 2026 | 240.20K | $15.83M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 44 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M sh · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M sh · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M sh · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M sh · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M sh · $102.34M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $83.52M · Q2 2026
- GW&K Investment Management, LLC 1.02M sh · $67.08M · Q3 2026
- Melqart Asset Management (UK) Ltd 767.52K sh · $65.39M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
- Deep Track Capital, LP 700.00K sh · $59.63M · Q2 2026
More on Capricorn Fund Managers Ltd
FAQ
How long has Capricorn Fund Managers Ltd held CYTK?
Capricorn Fund Managers Ltd has disclosed CYTK holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Capricorn Fund Managers Ltd's current position in CYTK?
As of Q3 2026, Capricorn Fund Managers Ltd holds 240.20K shares of CYTK (CYTOKINETICS INC), valued at $15.83M, representing 1.52% of its reported portfolio and ranking #19.
Has Capricorn Fund Managers Ltd been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Capricorn Fund Managers Ltd increased its position in CYTK. The position peaked in Q3 2026 at 240.20K shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.